Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation.

ABSTRACT: Introduction and objectives: Adequate anticoagulation control with vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF) improves health outcomes. Knowing how the economic burden depends on the degree of anticoagulation control may be relevant for decision makers. This study analyses health outcomes and costs in relation to the degree of control of anticoagulation with VKAs in NVAF in primary care using real-world data. Methods: The present study analyzes health outcomes and costs based on Rosendaal's time in therapeutic range (TTR), considering values of TTR > 70% to indicate adequate control. It was carried out using data from 2018, from the perspective of the health system, with a time horizon of 1 year, in 325 Primary Care Centers in Catalonia, Spain.

SUBMITTER: Dalmau Llorca MR 

PROVIDER: S-EPMC11818192 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature